NeuroScios
- Company typePrivate
- Founded2013
- HeadquartersGraz, Austria
- Headcount11–50
- GTM typeB2B
- OfferingServices
NeuroScios firmographics
Firmographics- Name
- NeuroScios
- Legal name
- Neuroscios GmbH
- Website
- https://neuroscios.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
NeuroScios industry classification
Industry- Product category
- Clinical Research Organization (CRO) Services — Neurological Trials
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industries
- Clinical CROs (Phase I–IV) (HLAGAAAA), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)
Keywords
Where NeuroScios is headquartered
LocationHeadquarters
- HQ city
- Graz
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
NeuroScios business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: Full-service CRO services for neurological clinical trials including study design, protocol development, trial management, patient recruitment, biomarker/imaging services, data management, safety reporting, and regulatory submissions. Revenue generated through service contracts with pharma and biotech sponsors.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Fixed-budget contracting for full-service clinical trial delivery |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NeuroScios product offering
Product offeringCore offering
NeuroScios is a full-service Contract Research Organization (CRO) focused exclusively on neurological clinical trials for pharmaceutical and biotech sponsors. It delivers end-to-end services including study design, protocol development, trial management, patient recruitment, biomarker and imaging (MRI, PET), cognitive testing, data management, safety reporting, and regulatory submissions (IND/CTA). The company also leverages its integration with the Sanos Group to provide dedicated clinical research sites, clinical trial supply, patient recruitment, and eCOA services.
Product overview
NeuroScios operates as a specialized full-service Contract Research Organization (CRO) focused exclusively on neurological clinical research. The company offers a unified portfolio of integrated services centered on neurological clinical trials, including study design and protocol development, trial management and oversight, patient recruitment through a global site network, biomarker and imaging capabilities, data management with safety reporting, and global trial execution. Through its partnership with Sanos Group, NeuroScios provides seamless access to dedicated clinical research sites, clinical trial supply, patient recruitment, and eCOA services. The core product is its comprehensive neurological clinical research service combining scientific expertise with operational excellence across all trial phases.
Differentiator
Problem solved
Functional benefit
Products and services
- Neurological Clinical Research Services Full-service Contract Research Organization (CRO) specializing in neurological clinical trials, providing end-to-end trial design, execution, and regulatory submission support for pharmaceutical and biotech sponsors.
- Study Design & Protocol Development Collaborative protocol development service covering endpoint selection, statistical planning, adaptive design, and submission strategies tailored for neurological clinical trials.
- Trial Management & Oversight Comprehensive project team oversight including vendor management, site monitoring, and risk mitigation ensuring execution aligned with timelines, budgets, and quality standards.
- Patient Recruitment & Site Network Access to global network of neurology research sites, digital recruitment platforms, patient registries, and KOL relationships enabling accelerated enrollment and high retention rates.
- Biomarker and Imaging Capabilities Integration of fluid biomarkers, imaging (MRI, PET), and digital tools for early signal detection, patient stratification, and novel endpoint utilization in CNS neurology trials.
- Data Management, Safety and Reporting Full clinical data management, biostatistics, pharmacovigilance, and medical writing services with centralized teams and validated systems ensuring data integrity and submission readiness.
- Neuroimaging Services Multi-site imaging standardization with 13+ years of experience including imaging protocol consultancy, site training, image collection, central reading, and statistical analysis support for MRI, PET, and CT endpoints.
- Cognitive Testing Services Expert cognitive test selection and rater training services with translational strategy support from preclinical models to clinical outcomes for Alzheimer's and cognitive disorder trials.
- Global Execution with Sanos Integration Integrated trial delivery combining in-house clinical IMP supply, biostatistics, site support, and regulatory expertise through Sanos Group partnership.
Quantifiable outcome
- 30+ clinical studies delivered successfully
- +1 more outcomes
Companies that use NeuroScios
Customer profileSegments2 records
Ideal customer profiles2 records
NeuroScios technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
NeuroScios partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SanoscoreIn 2024, NeuroScios became part of Sanos, a global multi-niche CRO. While leadership and scientific direction remain intact, NeuroScios benefits from broader in-house capabilities including dedicated clinical research sites, clinical trial supply, patient recruitment, and eCOA. This integration enhances ability to deliver high-quality neurological clinical trials from start to finish.
Scale indicators7 records
Recent moves4 records
Expansion highlights5 records
NeuroScios competitors and assessment
Company assessmentBroad incumbents
- IQVIA: World's largest CRO with extensive CNS/neurology capabilities and proprietary data assets. Competes with NeuroScios on large neurology programs where scale and integrated technology platforms matter.
- ICON plc: Global CRO with strong CNS and Alzheimer's trial experience following its PRA Health Sciences merger. Competes with NeuroScios for neurology programs while offering broader service portfolio.
- Covance / Labcorp Drug Development: Large CRO with established CNS and Alzheimer's clinical research capabilities, integrated with central laboratory services. Competes with NeuroScios particularly on biomarker and imaging-intensive CNS programs.
- Medpace: Mid-to-large global CRO with strong therapeutic specialization across multiple areas including CNS. Competes with NeuroScios for biotech neurology trial work with similar full-service model.
- Parexel: Major global CRO with dedicated neurology and rare disease therapeutic units. A broader incumbent competing with NeuroScios for CNS trial contracts but with much larger scale and global footprint.
- Syneos Health: Global full-service CRO with broad therapeutic area coverage including CNS/neurology. Larger scale and broader portfolio than NeuroScios but competes for the same pharma/biotech neurology trial sponsors.
Direct peers
- Clario: Clario provides clinical trial endpoint technology and services with significant neuroscience expertise, including eCOA, imaging, and CNS trial solutions. Directly competes with NeuroScios in delivering technology-enabled neurology clinical trial services.
- Premier Research: Specialty CRO with dedicated neurology and rare disease focus, similar in therapeutic specialization to NeuroScios. Directly comparable as a mid-sized specialty CRO targeting CNS drug developers.
- Sanos Group: Parent company of NeuroScios and a global multi-niche CRO with integrated clinical research sites, trial supply, patient recruitment, and eCOA services. Operates as a sibling/parent entity with overlapping CRO capabilities.
Emerging players
- CNS Healthcare (or comparable specialty CNS CRO): Specialty clinical research providers focused on CNS endpoints and neurology trials. Comparable in therapeutic focus though typically offering narrower service scope than full-service CROs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
NeuroScios social profiles
Digital presenceNeuroScios financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroScios leadership team
Management profileNumber of profiles
NeuroScios funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroScios M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroScios
What does NeuroScios do?
NeuroScios is a full-service Contract Research Organization (CRO) focused exclusively on neurological clinical trials for pharmaceutical and biotech sponsors. It delivers end-to-end services including study design, protocol development, trial management, patient recruitment, biomarker and imaging (MRI, PET), cognitive testing, data management, safety reporting, and regulatory submissions (IND/CTA). The company also leverages its integration with the Sanos Group to provide dedicated clinical research sites, clinical trial supply, patient recruitment, and eCOA services.
Is NeuroScios a public or private company?
NeuroScios is a private company. It is classified as corporate owned and is currently operating.
When was NeuroScios founded?
NeuroScios was founded in 2013. It employs 11 to 50 people.
Where is NeuroScios based?
NeuroScios is headquartered in Graz, Austria, in the Europe region.
How does NeuroScios make money?
One revenue line is on record: clinical Research Services.
Who are NeuroScios's main competitors?
Broad incumbents on record are IQVIA, ICON plc, Covance / Labcorp Drug Development, Medpace, Parexel and Syneos Health. Direct peers are Clario, Premier Research and Sanos Group. CNS Healthcare (or comparable specialty CNS CRO) is listed as an emerging player.
Does NeuroScios have an API?
No public API is recorded for NeuroScios.
What industry is NeuroScios in?
NeuroScios's product category is Clinical Research Organization (CRO) Services — Neurological Trials. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.